|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | Grand Central Station, PO Box 4777 |
Address2 |
|
City | New York |
State | NY |
Zip Code | 10163 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104060-12
|
||||||||
|
6. House ID# 432920001
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Ted Thompson |
Date | 10/21/2020 11:12:57 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 7663- Protecting Access to Post-COVID-19 Telehealth Act of 2020
H.R.7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020
Expand eligibility for paid family and medical leave for high-risk individuals during the pandemic
Telehealth guidelines for making the flexibilities permanent
Medicaid non-emergency medical transportation (NEMT)
Improving Seniors Timely Access to Care Act (H.R. 3107)
S. 1384, the Prescription Drug Rebate Reform Act of 2019
S.475 - RxCAP Act of 2019
H.R. 945/S. 286, the Mental Health Access Improvement Act of 2019
H.R. 601 - Medical Cannabis Research Act of 2019
Support of an out-of-pocket spending cap for Medicare Part D
Support for Value Based Arrangements in Medicare and Medicaid
Coronavirus Aid, Relief, and Economic Security Act
General information about Parkinson's disease, the need for research funding, and protecting access to care
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ted |
Thompson |
|
Senior Vice President, Public Policy |
|
Aaron |
Polacek |
|
Public Policy Officer |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.3772- Medicare Diagnostic Radiopharmaceutical Payment Equality Act of 2019
H.R. 7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020
Medicaid non-emergency medical transportation (NEMT)
S.475 - RxCAP Act of 2019
H.R. 945/S. 286, the Mental Health Access Improvement Act of 2019
Support of an out-of-pocket spending cap for Medicare Part D
Support for Value Based Arrangements in Medicare and Medicaid
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ted |
Thompson |
|
Senior Vice President, Public Policy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Environmental agitators of Parkinson's disease
HR 7940 / S 4406 Protect Americas Children from Toxic Pesticides Act
HR 230 Ban Toxic Pesticides Act of 2019
HR 3817 Protect Against Paraquat Act
17. House(s) of Congress and Federal agencies Check if None
Environmental Protection Agency (EPA), Natl Institutes of Health (NIH), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ted |
Thompson |
|
Senior Vice President, Public Policy |
|
Brittany |
Meyer |
|
Senior Associate Director, Public Policy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) at the Department of Veterans Affairs and the Medical Services Account
Federal appropriations for National Institutes of Health and the Centers for Disease Control; Federal appropriations for Department of Defense Medical Research Programs
Federal appropriations for Food and Drug Administration
Federal appropriations for Department of Defense Medical Research Programs
The Coronavirus Aid, Relief, and Economic Security Act (CARES)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ted |
Thompson |
|
Senior Vice President, Public Policy |
|
Brittany |
Meyer |
|
Senior Associate Director, Public Policy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Support of pharmaceutical innovation
Changes to The Prescription Drug User Fee Act
S.475 - RxCAP Act of 2019
Support of an out-of-pocket spending cap for Medicare Part D
Support for Value Based Arrangements in Medicare and Medicaid
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ted |
Thompson |
|
Senior Vice President, Public Policy |
|
Brittany |
Meyer |
|
Senior Associate Director, Public Policy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) at the Department of Veterans Affairs and the Medical Services Account
H.R.663 / S. 191 - Burn Pits Accountability Act
H.R. 2500- National Defense Authorization Act for Fiscal year 2020
S. 4049-National Defense Authorization Act for Fiscal Year 2021
H.R.5610- Fair Care for Vietnam Veterans Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brittany |
Meyer |
|
Senior Associate Director, Public Policy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Environmental Protection Agency's Transparency Rule
Cost / Benefit analysis
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brittany |
Meyer |
|
Senior Associate Director, Public Policy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |